Superlab Suisse opens largest private lab space in Basel

Superlab Suisse has announced the opening of its latest facility in Basel, marking a significant expansion in its provision of dedicated laboratory and research spaces for life science and biotech startups. The new Basel location, spanning over 4770 square metres, is set to become the largest private lab space in Switzerland. This facility, located within the bustling Stcki Park, adds to Superlab Suisse's mission to enhance scientific research infrastructure in the country's dynamic life sciences sector.

The Basel site will join Superlab Suisse's existing location in Lausanne, which has seen success through support from institutions like Biople Lausanne and InnoVaud. This expansion is intended to meet the substantial demand for ready-to-use laboratory spaces, which have traditionally been limited due to the high costs associated with lab construction and operation.

Zhang Xi, CEO of Superlab Suisse, expressed enthusiasm about the new development: "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma. Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover, is our mantra."

Historically, life sciences and biotech companies have faced significant challenges due to the prohibitive costs of establishing and maintaining laboratory spaces. This has often redirected essential resources away from research, delaying progress in developing products. Superlab Suisse aims to address these issues through its serviced BSL1 and BSL2 labs, providing a new industry standard that eliminates the hurdles associated with lab construction and allows companies to focus on their scientific pursuits.

The new Basel facility is strategically located amongst industry giants such as Novartis, Roche, and other key players, enhancing potential for commercial collaborations and scientific breakthroughs. The site offers ready-to-move-in laboratories equipped with the latest technology and operational support services. Furthermore, users in Basel will have access to amenities and facilities at other Superlab Suisse locations, such as Lausanne.

Skyhawk Therapeutics is one of the first companies to secure a space at the new Basel location. The company recently announced a research collaboration with Ipsen, focusing on RNA targeting in rare neurological diseases. This demonstrates the practical applications and immediate benefits that Superlab Suisse's facilities can facilitate.

In addition to the Basel location, Superlab Suisse has announced plans for a third site in Zurich Schlieren, scheduled to open in March 2025. This new facility will aim to cater to the diverse needs of startups, spin-offs, and established companies in the life sciences sector, further solidifying Superlab Suisse's position as a leading provider of laboratory-as-a-service solutions.

Dr. Rajwinder Lehal, CEO of biotech business Cellestia, commented on the benefits of Superlab Suisse's offering: "Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation. Superlab provided us with state-of-the-art infrastructure and equipment that we needed to hit the ground running from day one."

Emmanuel Savioz, CEO and Chairman of Tigen Pharma, added: "Superlab is a great place to work in a vibrant scientific community. Our team at Tigen can focus on growth, supported by state-of-the-art facilities, latest equipment and a competent and fun Superlab team to support on-site."

This expansion of Superlab Suisse reflects a broader trend towards flexible, collaborative lab environments in the life sciences industry. By providing innovative laboratory solutions in key scientific hubs, Superlab Suisse is addressing the critical needs of today's life science companies, facilitating greater focus on research and innovation.